TICKERNERD
Menu
ACBACBHealthcare · Drug Manufacturers - Specialty & Generic

ACB Stock Forecast: Aurora Cannabis, Inc. Price Predictions for 2026-2027

Last close, 11 Aug 2026
$3.49
+20.59% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 35 of 100 as at 10 Aug 2026 — in the lower half.

Market cap
$178.4M
Ticker Nerd rank
35 / 100
Median analyst target
—
Analysts covering
6
Total return, dividends reinvested
1W
+24.0%
1M
+28.6%
YTD
−17.4%
1Y
−33.1%
From 52W high
−44.1%
From 52W low
+35.1%
$2.58
$6.23
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ACB stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Aurora Cannabis, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 10 Aug 2026
35 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
76
Issuance
70
Size
69
Revisions
53
Volatility
50
Quality
45
Value
22
Growth
18
Momentum
13

Accruals (76): Reported profit is backed by cash, and the company is not expanding recklessly.

Momentum (13): The shares have been drifting down relative to others.

Wall Street

ACB stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ACB, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$2.00$3.00$4.00$5.00$6.00Oct 25Jan 26Apr 26Jul 26ACB

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says6 analysts
3 Buy3 Hold0 Sell
Recent analyst actionsNewest first

Of the 20 most recent actions, 0 moved their price target up and 4 moved it down.

DateFirmActionRatingTarget
27 June 2024Zuanic & AssociatesInitiatesNeutral—
16 June 2023CIBCMaintainsNeutral$1.75 → $1.00
15 June 2023Canaccord GenuityMaintainsHold$1.50 → $0.80
13 Feb 2023CIBCMaintainsNeutral$2.25 → $1.75
21 Sept 2022Piper SandlerMaintainsNeutral$4.00 → $3.00
28 Sept 2021MKM PartnersUpgradeNeutral—
18 Dec 2020BMO CapitalDowngradeUnderperform$9.00
25 Nov 2020B of A SecuritiesDowngradeNeutral—
25 Nov 2020Bank of AmericaDowngradeNeutral—
25 Nov 2020Cowen & Co.InitiatesOutperform—
25 Nov 2020DesjardinsInitiatesBuy—
25 Nov 2020JefferiesInitiatesBuy—
25 Nov 2020Ladenburg ThalmannDowngradeNeutral—
25 Nov 2020MKM PartnersInitiatesSell—
25 Nov 2020NeedhamInitiatesHold—
25 Nov 2020Piper JaffrayMaintainsNeutral—
25 Nov 2020Piper SandlerMaintainsNeutral—
25 Nov 2020Seaport GlobalInitiatesNeutral—
25 Nov 2020StifelDowngradeSell—
25 Nov 2020Stifel NicolausInitiatesHold—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ACB appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

ACB analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Aurora Cannabis, Inc. (ACB) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
20.8×

Cheaper than 38% of US stocks

Price / sales
0.6×

Cheaper than 81% of US stocks

Price / book
0.4×

Cheaper than 86% of US stocks

EV / EBITDA
−3.9×

Cheaper than 77% of US stocks

Growth & margins
Revenue growth (YoY)
−8.8%

Higher than 16% of US stocks

Earnings growth (YoY)
−31.1%

Higher than 15% of US stocks

Gross margin
52.7%

Higher than 66% of US stocks

Operating margin
−12.9%

Higher than 24% of US stocks

Net margin
−38.3%

Higher than 12% of US stocks

Returns & dividend
Return on equity
−9.4%

Higher than 36% of US stocks

Return on assets
−3.7%

Higher than 33% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

ACB vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
ACBAurora Cannabis, Inc.$178.4M
35
DERMJourney Medical Corp.$176.0M
67
LFCRLifecore Biomedical, Inc.$174.6M
5
CRDLCardiol Therapeutics, Inc.$171.8M
49
SIGASIGA Technologies, Inc.$209.9M
42
AKBAAkebia Therapeutics, Inc.$226.1M
73
EBSEmergent BioSolutions, Inc.$231.4M
92

The rank is the raw material. Whether the rules would actually own Aurora Cannabis, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ACB news & analysis

Curaleaf Just Announced a Hostile Takeover Bid for Aurora Cannabis. Here's What This Means for Investors.

The Motley Fool · 12 Aug 2026neutral

Curaleaf has announced a hostile takeover bid for Aurora Cannabis. Aurora has criticized key aspects of the bid but stated it will consider it, noting that its major appeal lies in its strong medical marijuana business.

Why it matters — ACB watchers would care because a hostile takeover bid from Curaleaf directly affects Aurora's ownership and future, with its strong medical marijuana operations seen as the key draw.

AURORA CANNABIS INC. RESPONDS TO PRESS RELEASE OF CURALEAF HOLDINGS, INC.

PRNewsWire · 11 Aug 2026neutral

Aurora Cannabis issued a response to a press release from Curaleaf Holdings regarding Curaleaf's stated intention to launch an unsolicited takeover bid for all issued and outstanding Aurora common shares at an implied consideration of US$4.00 per share. Aurora confirmed it received letters from Curaleaf dated June 23, 2026 and July 7, 2026 outlining the acquisition proposals.

Why it matters — This confirms that Aurora has received a formal unsolicited takeover approach from Curaleaf, information directly relevant to ACB investors tracking a potential acquisition.

Curaleaf launches hostile bid for Aurora Cannabis

Proactive Investors · 11 Aug 2026neutral

Curaleaf Holdings has launched a hostile bid to acquire Aurora Cannabis, offering Aurora shareholders a combination of Curaleaf shares and cash valued at US$4 per Aurora share. Under the proposed transaction, Aurora shareholders would receive 0.3463 Curaleaf shares plus US$0.75 in cash for each Aurora share, as Curaleaf seeks to combine the companies' international cannabis operations.

Why it matters — Aurora Cannabis shareholders now face an unsolicited takeover proposal that could change the company's ownership and strategic direction.

Tilray Brands stock rises as Curaleaf plots hostile takeover for Aurora

Invezz · 11 Aug 2026negative

A report indicated that Curaleaf is planning a hostile takeover bid for Aurora Cannabis, causing cannabis stocks including Tilray Brands to rise.

Why it matters — This news directly affects Aurora Cannabis as the target of a potential hostile takeover attempt, which could significantly impact the company's future direction and shareholder value.

Curaleaf Plans Hostile Bid for Rival Aurora Cannabis

WSJ · 11 Aug 2026neutral

Curaleaf plans to launch a $272 million unsolicited, or hostile, takeover bid to acquire Canadian cannabis company Aurora Cannabis, after Aurora's board repeatedly refused to negotiate an acquisition deal.

Why it matters — A hostile takeover attempt could change Aurora's ownership and control, making this an important corporate governance development for ACB watchers.

FAQ

Frequently asked questions about ACB stock

Is ACB stock a buy right now?

Of the 6 analysts covering Aurora Cannabis, Inc., 3 rate it a Buy, 3 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Aurora Cannabis, Inc. 35 out of 100 across roughly 4,600 US stocks as at 10 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ACB?

As at 10 Aug 2026, Aurora Cannabis, Inc. ranks 35 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (76 of 100).

What is the ACB stock forecast for 2030?

No analyst covering Aurora Cannabis, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ACB are extrapolating price history, which says nothing about the business.

How has ACB stock performed over the past year?

Aurora Cannabis, Inc. returned -33.1% over the 12 months to 11 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Aurora Cannabis, Inc. do?

Aurora Cannabis Inc. is a Canadian cannabis producer specializing in the cultivation, processing, and sale of medical and adult-use cannabis products.

What is the latest news on ACB?

The most recent item we track (The Motley Fool, 12 Aug 2026): "Curaleaf Just Announced a Hostile Takeover Bid for Aurora Cannabis. Here's What This Means for Investors.". Curaleaf has announced a hostile takeover bid for Aurora Cannabis. Aurora has criticized key aspects of the bid but stated it will consider it, noting that its major appeal lies in its strong medical marijuana business.

Company

About Aurora Cannabis, Inc.

Aurora Cannabis Inc. is a Canadian cannabis producer specializing in the cultivation, processing, and sale of medical and adult-use cannabis products. Headquartered in Edmonton, Alberta, the company operates through two main segments: Cannabis and Plant Propagation, providing both finished cannabis goods and starter materials for commercial growers. Aurora Cannabis offers dried flower, pre-rolls, oils, vapes, edibles, and derivative products, addressing a range of consumer and patient needs in regulated markets. It markets its products under multiple brands and participates in both domestic and international medical cannabis channels, supported by export agreements and partnerships. In addition, its plant propagation business supplies agricultural and horticultural sectors with high-quality starter plants. Positioned within the healthcare and specialty drug manufacturing industry, Aurora Cannabis plays a notable role in the evolving legal cannabis market, linking pharmaceutical-style production standards with consumer and medical demand across Canada and select global regions.

CEO Mr. Miguel Martin · 1,028 employees · Canada · https://www.auroramj.com